News

News 04.01.2023 BILLERICA, Massachusetts and SCHLIEREN, Switzerland – January 4, 2023 – Bruker Corporation (Nasdaq: BRKR) and Switzerland-based Biognosys AG today announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys. Several of Biognosys’ earlier investors have sold their...

Events, External events
Event date: 19.02.2023 In today’s competitive environment, the gene to First In Human (FIH) journey is complicated and more challenging than ever. Competitors are chasing the same indications as well as the finite funding available. There is increased pressure to get the candidate into the clinic as fast as possible. Amidst overwhelming uncertainty,...

Events, External events
Event date: 23.05.2023 May 23, 2023 | 9am - 6pm Technopark Zurich Aim & Motivation Life Science Zurich Impact «Data for Health» is a one-day multi-track meeting that provides a plat- form for scientists from academia and industry to present their projects to potential collabora- tors and investors thus stimulating a dialogue between research, healthcare and economy with a focus on translational...

News 13.12.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, presented today new preclinical data showing its DARPin T-cell engager MP0533 can induce preferential killing of cells expressing...

News 08.12.2022 Schlieren, Zurich, 8 December 2022 – Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announces the appointment of Otmane Boussif, DSc as Chief Technology Officer (CTO). Otmane brings more than 25 years of experience in shaping and leading biopharmaceutical...